204 related articles for article (PubMed ID: 27574825)
1. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells.
Saydaminova K; Strauss R; Xie M; Bartek J; Richter M; van Rensburg R; Drescher C; Ehrhardt A; Ding S; Lieber A
Cancer Biol Ther; 2016 Oct; 17(10):1079-1088. PubMed ID: 27574825
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
3. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
[TBL] [Abstract][Full Text] [Related]
4. Lumiflavin increases the sensitivity of ovarian cancer stem-like cells to cisplatin by interfering with riboflavin.
Yang R; Wei Z; Wu S
J Cell Mol Med; 2019 Aug; 23(8):5329-5339. PubMed ID: 31187586
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin induces stemness in ovarian cancer.
Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
8. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
10. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition.
Deng S; Wong CKC; Lai HC; Wong AST
Oncotarget; 2017 Apr; 8(16):25897-25914. PubMed ID: 27825116
[TBL] [Abstract][Full Text] [Related]
12. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
[TBL] [Abstract][Full Text] [Related]
13. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
14. Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells.
Lee H; Kim JW; Kim DK; Choi DK; Lee S; Yu JH; Kwon OB; Lee J; Lee DS; Kim JH; Min SH
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230901
[TBL] [Abstract][Full Text] [Related]
15. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
16. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
Bharti R; Dey G; Khan D; Myers A; Huffman OG; Saygin C; Braley C; Richards E; Sangwan N; Willard B; Lathia JD; Fox PL; Lin F; Jha BK; Brown JM; Yu JS; Dwidar M; Joehlin-Price A; Vargas R; Michener CM; Longworth MS; Reizes O
Mol Cancer; 2024 Jun; 23(1):121. PubMed ID: 38853277
[TBL] [Abstract][Full Text] [Related]
17. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
[TBL] [Abstract][Full Text] [Related]
18. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
19. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
